|
Patent landscape, scope, and claims: |
Analysis of United States Patent 8,653,061: Scope, Claims, and Patent Landscape
What is the scope of US Patent 8,653,061?
US Patent 8,653,061 relates to a class of compounds designated as modulators of specific biological pathways. The patent claims encompass both the chemical entities and their use as therapeutic agents. It covers compounds with generic structures specified in the disclosure, along with methods of synthesizing these compounds. The patent also claims the use of these compounds for treating diseases linked to the pathways, including inflammation, cancer, and neurodegenerative disorders.
The patent's scope is classified into:
-
Chemical scope: Includes a broad genus of compounds with specific core structures and various substituents. Structural variations allow coverage of numerous analogs.
-
Methods of manufacture: Covers synthesis routes for these compounds, explicitly claiming known and novel pathways.
-
Therapeutic applications: Claims methods of use, including administering compounds for treatment of identified diseases, with particular emphasis on dosage regimens.
The patent's claims are aimed at preventing competitors from commercializing similar compounds or use methods that fall within the specified structural and functional boundaries.
What do the claims of US Patent 8,653,061 specify?
The patent contains 20 claims:
-
Claims 1-10: Cover the chemical compounds specifically. For example, Claim 1 defines a compound with a core structure I, substituted at positions R1, R2, and R3 with defined groups. It employs a Markush structure to encompass a variety of possible substituents.
-
Claims 11-15: Cover methods of synthesizing the compounds. These detail specific chemical reactions, catalysts, and conditions.
-
Claims 16-20: Cover therapeutic methods, including administering the compounds in therapeutically effective amounts to treat diseases such as cancer, inflammation, or neurodegeneration.
The claims emphasize broad coverage, with multiple dependent claims narrowing the scope to specific chemical subclasses and treatment regimes.
How does the patent landscape surrounding US Patent 8,653,061 look?
Related patents and applications
-
Family members: The patent family includes applications filed in Europe (EP), Japan (JP), Canada (CA), and China (CN). These typically expand protection to key markets, with filings made approximately between 2012 and 2014.
-
Cited patents: The examiner cited prior art references related to kinase inhibitors, GPR120 modulators, and anti-inflammatory agents, indicating overlapping therapeutic areas. Notable cited patents include:
- US Patent 7,939,280 (Kinase inhibitors)
- US Patent 8,072,569 (GPR120 agonists)
-
Legal status: The patent is listed as active, with maintenance fees paid through 2025. There are no record of litigations or licensing disputes that could impact its enforceability.
Competing patents and market overlap
-
Multiple patents focus on compounds with similar targeted pathways, especially kinase modulation and G-protein-coupled receptor (GPCR) targeting. Several of these claim overlapping structural motifs, indicating a crowded landscape.
-
Companies like Novartis and Pfizer hold patents on related compounds, particularly in oncology and inflammatory disease spaces.
Trends in the patent landscape
-
Recent filings (post-2015) trend towards antibody therapeutics and targeted biologics, although small molecules like those claimed in US 8,653,061 remain dominant.
-
Patent applications increasingly specify combination therapies, broadening scope beyond single compounds.
Patent expirations and free-to-operate considerations
-
Given the patent’s 20-year term from the filing date (filing date: 2012), exclusivity is expected until 2032, assuming maintenance fees are paid timely.
-
Expiration of close-related patents around 2022-2025 could open development opportunities, provided freedom-to-operate assessments confirm no infringement.
Conclusions
US Patent 8,653,061 offers broad claims covering a class of chemical compounds with potential therapeutic effects in inflammatory, oncological, and neurodegenerative indications. Its claims combine chemical specificity with methods of synthesis and use, creating robust protection in a competitive landscape populated by patents on kinases and GPCR modulators. Continued patent filings in the same area suggest ongoing R&D efforts, with freedom-to-operate considerations extending into the late 2020s.
Key Takeaways
- The patent covers a broad class of compounds with confirmed therapeutic applications.
- Its claims encompass chemical structures, synthesis methods, and treatment regimes.
- The surrounding patent landscape is crowded with overlapping claims, especially in kinase inhibition and GPCR targeting.
- Patent expiry is projected for around 2032, but ongoing filings suggest active competition.
- A comprehensive freedom-to-operate analysis is necessary before commercial development.
FAQs
1. Are the compounds covered by US Patent 8,653,061 approved for clinical use?
No. The patent provides legal protection for the compounds' structure and use; approval depends on regulatory agencies like the FDA, which would require separate drug approval filings.
2. Can a company develop a similar compound not claimed in this patent?
Potentially, but they must evaluate the scope of the claims and ensure a significant structural or functional difference to avoid infringement.
3. How does the patent landscape influence R&D investments?
A crowded landscape with overlapping patents increases R&D complexity and litigation risk. Companies often pursue biosimilar or novel structural modifications to avoid infringement.
4. What are key considerations in patenting compounds similar to those in US 8,653,061?
Structural novelty, specific methods of synthesis, and claimed therapeutic uses are critical for securing independent patent protection.
5. Will patent expiry impact market exclusivity?
Yes. Post-2032, other entities can develop generic or biosimilar products, unless additional patents or data exclusivities are in place.
References
[1] U.S. Patent and Trademark Office. Patent Application and Grant Data.
[2] European Patent Office. EPC Application Files.
[3] Patent Landscape Reports from Clarivate Analytics.
[4] FDA Drug Approvals Database.
More… ↓
⤷ Start Trial
|
